68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.
Carcinoid Cancer|Neuroendocrine Tumors|Medullary Thyroid Cancer|Cancers Expressing Somatostatin Receptors
DRUG: 68Ga DOTATATE
This is an expanded access study with a total of 300 participants with NET and suspected SSTR positive tumors. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive 68Ga-DOTATATE and will undergo a PET/CT imaging study. All patients referred by Oncologists will be screened by a UCLA Nuclear Medicine physician and then accepted for scanning if clinically appropriate.